Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Atmos Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Atmos Energy Corporation trades at $168.76 (market cap $28.59B). The key difference: Alnylam Pharmaceuticals, Inc. and Atmos Energy Corporation are close in size by market cap, and Atmos Energy Corporation pays a 2.36% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ATO | |
|---|---|---|
Market Cap | $29.60B | $28.59B |
Sector | Health | Utilities |
52-Week High | $491.22 | $192.25 |
52-Week Low | $205.48 | $162.44 |
Enterprise Value | $27.56B | $38.40B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Atmos Energy (ATO) trades at $169.68, up 1.05% today, with a bearish technical signal but strong fundamentals including a 28.5% net income margin and consistent dividend payments. Recent Q3 2026 earnings beat estimates with EPS of $1.43 versus $1.35 expected, and the company reaffirmed fiscal 2026 guidance. The stock shows neutral oscillators but bearish moving averages, with key support at $168.
The outlook is mixed: analyst consensus is a Buy with a $190.57 price target, but technical indicators suggest near-term caution. Risks include high capital expenditures impacting cash flow and interest rate sensitivity. Upside potential hinges on execution of rate hikes and infrastructure investments, while downside risks involve regulatory changes and economic slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
